Post-translational modification with the ubiquitin-like SUMO protein is involved in the regulation of many cellular key processes. The SUMO system modulates signal transduction pathways, including cytokine, Wnt, growth factor and steroid hormone signalling. SUMO frequently restrains the activity of downstream transcription factors in these pathways presumably by facilitating the recruitment of corepressors or mediating the assembly of repressor complexes. Additionally, evidence is accumulating that SUMO controls pathways important for the surveillance of genome integrity. SUMO regulates the PML/p53 tumour suppressor network, a key determinant in the cellular response to DNA damage. Moreover, proteins that maintain genomic stability by functioning at the interface between DNA replication, recombination and repair processes undergo SUMOylation. We will discuss some key findings that exemplify the role of SUMO in transcriptional regulation and genome surveillance.
The SUMO pathway: a ubiquitin-like modification system Ubiquitin and ubiquitin-like modification systems are related pathways that covalently attach a protein modifier to a lysine residue of a target protein. The prototypic modifier ubiquitin classically marks proteins for proteasomal destruction typically when polymeric chains of ubiquitin assemble via ubiquitin-ubiquitin isopeptide-linkages on ubiquitin's lysine 48 residue (Weissman, 2001) . Importantly, however, several nontraditional roles of ubiquitination, including endocytosis, transcriptional regulation and DNA repair have been elucidated. In these cases, proteins are frequently tagged with mono-ubiquitin or alternatively linked ubiquitin chains (Pickart, 2000) . The discovery of a whole family of ubiquitin-like modifiers, which are not directly involved in protein degradation, has further expanded the ubiquitin field (Jentsch and Pyrowolakis, 2000) . One member of this family is the SUMO protein, also known as smt3, sentrin, GMP1 or PIC1 (Melchior, 2000; Muller et al., 2001; Seeler and Dejean, 2003) .
Initially identified in the yeast Saccharomyces cerevisiae, SUMO forms were later described in all eukaryotes. In humans, three SUMO forms, SUMO-1, SUMO-2 and SUMO-3 are expressed from three different genes. SUMO-1 shows about 50% sequence identity to SUMO-2/3, which are almost identical. Research has mainly focused on SUMO-1, a protein of 101 amino acids that shares 18% sequence identity with ubiquitin. In addition to the sequence homology, SUMO and ubiquitin have a common three-dimensional structure. The conjugation of SUMO to target proteins, termed SUMOylation, leads to the formation of an isopeptide bond between the C-terminus of SUMO and an e-amino group of a lysine residue in the target protein. In most cases, the lysine residue is embedded in a consensus sequence composed of a characteristic cKxE motif, where c is a large hydrophobic residue. SUMOylation proceeds via a multistep pathway that is mechanistically analogous to ubiquitination, but uses a SUMO-specific enzymatic machinery (Figure 1 ). SUMO is synthesized as a precursor protein that is C-terminally processed by a class of cysteine proteases, termed SUMO-proteases or sentrin-specific (SENPs/SUSPs). Subsequently, the conjugation to proteins involves the ATP-dependent dimeric SUMO activating E1 enzyme (AOS1/UBA2) and the E2 conjugating enzyme Ubc9. In the ubiquitinpathway, one additional factor, called E3 or ubiquitinprotein ligase, is required in most cases for conjugation of ubiquitin to the target protein. E3 ubiquitin ligases are considered to trigger ubiquitination by recruiting ubiquitin-conjugating enzymes to the target proteins (Weissman, 2001) . Two major classes of ubiquitin ligases, HECT-domain and RING-type ligases, have been identified. HECT E3s catalyse ubiquitination by forming thioester intermediates between ubiquitin and a conserved cysteine residue in the HECT domain. RINGtype ligases merely function as adaptor molecules that have the ability to bind both the substrate and the E2. Recently, E3-like factors that stimulate SUMO conjugation have also been identified as pivotal players in the SUMO pathway.
E3-like ligases and isopeptidases as regulators in the SUMO pathway
Based on pioneering work in the yeast S. cerevisiae (Johnson and Gupta, 2001; Takahashi et al., 2001a, b) , it was found that members of the mammalian Protein Inhibitor of Activated STAT (PIAS) family exert SUMO-ligase activity towards various transcriptional regulators (Kahyo et al., 2001; Sachdev et al., 2001; Kotaja et al., 2002b; Muller, 2002, 2003) . PIAS proteins were initially described as negative regulators of STAT transcription factors (Shuai, 2000) . In humans at least four variants, PIAS1, PIAS3, the a and b splice variants of PIASx and PIASy are found. All are characterized by the central cysteine-rich SP-RING domain, which is essential for the E3-like activity and shares similarity with the RING motif that defines a subclass of ubiquitin ligases (Hochstrasser, 2001) . The concept of E3-like activities in the SUMO system has been extended by the identification of the PIASunrelated nucleoporin, RanBP2 and the polycomb protein hPC2 as new types of E3-like SUMO ligases Kagey et al., 2003) . Surprisingly, RanBP2 and hPC2 do not show any sequence similarity to known ubiquitin ligases. Currently known in vitro targets for RanBP2-mediated SUMOylation are the nuclear body component Sp100, the histone deacetylase HDAC4 and the ubiquitin-ligase Mdm2 Miyauchi et al., 2002; . The only identified SUMO targets for hPC2 so far are the transcriptional corepressors CtBP1 and CtBP2 (Kagey et al., 2003) . The mode of action of the SUMO E3-like factors is not yet fully understood. Structural studies have shown that Ubc9 makes direct contact with the cKxE SUMOylation motif indicating that in contrast to E2 enzymes of the ubiquitin system, the SUMO E2 enzyme itself appears to be critical for substrate recognition (Bernier-Villamor et al., 2002) . The role of the ligases might be to stabilize the interaction between Ubc9 and the substrate. This concept is supported by the finding that PIAS proteins and hPC2 can make physical contact with both Ubc9 and the SUMO target protein. Interestingly, in the case of PIAS ligases SUMOylation of the target protein further stabilizes the binding to PIAS proteins most likely through a defined SUMO recognition motif within PIAS (Minty et al., 2000; Sachdev et al., 2001; Kotaja et al., 2002b) .
A hallmark of all three types of SUMO ligases is their localization to specific subcellular complexes indicating that these structures may serve as modification platforms. RanBP2 is part of the nuclear transport machinery in the nuclear pore complex, where it functions as a docking factor of transport complexes. A first link between SUMOylation and nucleocytoplasmatic transport was established by the initial finding that the import factor RanGAP1 is targeted to the nuclear pore upon SUMOylation (Matunis et al., 1996; Mahajan et al., 1997) . In addition, SUMO conjugation was shown to control the nucleocytoplasmic distribution of various proteins, such as the Drosophila transcription factor Bicoid (Epps and Tanda, 1998) . Work in Dictyostelium on the MAP kinase MEK-1 revealed that SUMOylation is required for MEK1's translocation from the nucleus to the cytosol (Galy et al., 2002) . A similar mechanism was proposed recently for the transcriptional repressor TEL (Wood et al., 2003) . The localization of a SUMO-ligase at the nuclear pore now strengthens the idea that SUMOylation is coupled to nuclear transport processes. This particular aspect of the SUMO system has been expertly reviewed recently and will not be further developed here .
hPc2, a chromo-domain-containing protein, is found in nuclear foci termed PcG bodies. Other components of this mammalian polycomb complex are the RING finger proteins Ring1 and Bmi1, the SUMO targets CtBP1/ CtBP2 and chromatin remodelling factors that possess histone deacetylase and methyltransferase activity (Orlando, 2003) . Polycomb complexes mediate gene silencing by inducing a heterochromatin-like state of genes, mainly through the induction of post-translational modifications of histone tails. The association of E3-like SUMO activity with PcG bodies revealed a completely new aspect of these structures. Considering the role of SUMO in the assembly of another type of nuclear foci, the PML nuclear bodies (NBs), it is tempting to speculate that SUMOylation may be implicated in the formation of PcG bodies or in targeting proteins to these structures.
PIAS-type E3-like factors concentrate in nuclear foci that partially overlap with PML NBs. The biological function of NBs has not yet been fully elucidated, but the presence of various transcription factors and transcriptional coregulators in NBs argues for a role in the control of transcriptional processes (Zhong et al., 2000) . Additionally, several key proteins implicated in DNA replication, recombination and repair, including the RecA helicase Rad51 and the RecQ helicases bloom syndrome protein (Blm) and Werner protein (WRN), localize to a subset of PML NBs in the late S phase and after DNA damage, suggesting that a subpopulation of PML NBs participate in DNA replication and repair processes (see below). PML NBs likely play a central role in the SUMO system since most proteins localizing to these structures were found to be SUMOylated Dejean, 1999, 2001) . Several lines of Figure 1 Pathway of SUMO conjugation/deconjugation. SUMO is synthesized as a precursor and C-terminally processed (arrowhead). The conjugation involves SUMO activating E1 enzyme (AOS1/UBA2) and an E2 conjugating enzyme (Ubc9) that form thioesters (S) with the modifier. E3-like factors stimulate the attachment to specific lysine residues within a target protein. The cleavage of SUMO from its target proteins is catalysed by the SUSP/SENP isopeptidase family evidence indicate that SUMOylation is implicated in the dynamic regulation of NBs. In particular, modification of PML, the NB core component, is essential for the assembly of NBs and for recruitment of NB-associated proteins. Recent data demonstrate that PIAS proteins are also able to trigger the recruitment of transcription factors into NBs providing a further link between the SUMO modification system and NB targeting.
Importantly, SUMOylation is a reversible and dynamic process. The importance of deconjugating SUMO from target proteins is best illustrated by genetic data from yeast showing that like conjugation, deconjugation is needed for viability (Li and Hochstrasser, 1999) . The removal of SUMO is catalysed by SUMOspecific isopeptidases of the SUSP/SENP family. In humans, seven members of this family have been identified so far . All are characterized by a homologous 200 amino-acid sequence, known as ubiquitin-like protease (ULP) domain, which harbours the catalytically active region. The target specificity of the various SENPs/SUSPs is only beginning to be uncovered. Interestingly, however, like the SUMO ligases, the isopeptidases exhibit different intracellular localization and are frequently found in specific substructures, suggesting that sequestration may be an important determinant for their substrate specificity. SENP1, for instance, is found in PML NBs and consequently cleaves SUMO from PML . SENP2, as well as a subfraction of the yeast Ulp1 protein, localize to the nucleoplasmic face of the nuclear pore complex pointing to a role in nuclear transport processes (Takahashi et al., 2000; Hang and Dasso, 2002; Zhang et al., 2002a; Panse et al., 2003) . SENP3 (also known as SMT3IP1) in turn concentrates in the nucleolus, implying that its activity is restricted to nucleolar substrates (Nishida et al., 2000) .
The diversification of the SUMO machinery with multiple E3-like activities and isopeptidases assures a highly specific and tight regulation of the SUMOylation pathway, making it an important system for the control of various cellular processes. In the following, we will focus on the role of the SUMO system in the control of cellular signalling pathways and genome integrity.
SUMO as a regulator of signalling pathways
Distinct signalling pathways have evolved in metazoa to transduce extracellular signals to the cell nucleus. A common feature of these pathways is the activation of specific target genes by signal-dependent transcription factors. Typically, the pathways are activated by the binding of a ligand to a transmembrane receptor, which in turn leads to the modification of cytosolic transducers. Subsequently, these transducers activate transcription factors that ultimately alter gene expression. Recent data indicate that a major function of the SUMOsystem is to restrain the activity of transcription factors in diverse signalling pathways. The PIAS proteins appear to be important players in this process since they act as negative regulators and E3-like SUMO ligases for various transcriptional activators.
Cytokine signalling
STATs, a family of seven highly homologous transcription factors, induce the expression of specific genes in response to cytokines (Levy and Darnell, 2002) . Binding of a cytokine to a receptor at the cell surface initiates a cascade of phosphorylation leading to the formation of STAT homo-or heterodimers that translocate to the nucleus and bind to a cognate DNA-binding motif in the promoter region of target genes. In the nucleus, PIAS proteins act as major negative regulators of the activated STATs. An involvement of SUMO modification in this process is inferred from recent reports demonstrating that PIAS1 and PIASx stimulate SUMO modification of STAT1 at a distinct lysine residue that is conserved in other members of the STAT family (Rogers et al., 2003; Ungureanu et al., 2003) . Although SUMOylation does not seem to be absolutely required for PIAS-induced transcriptional repression, a SUMOylation-deficient STAT1 protein with the SUMO-attachment site changed to an arginine, shows an increase of transcriptional activity in response to IFN-g when compared to the wild-type protein. This indicates that SUMO modification at least contributes to the attenuation of STAT activity. Considering that constitutive activation of STATs induces cellular transformation and is frequently observed in human cancers, alterations in the SUMO pathway may thus be implicated in oncogenesis. In support of this idea, constitutive activation of STAT3 in anaplastic lymphoma is associated with downregulation of PIAS3 (Zhang et al., 2002b) .
Wnt signalling
Wnt signalling represents another example of a pathway that is misregulated in a variety of human cancers (Moon et al., 2002) . Constitutive activation of the bipartite transcription factor b-catenin-TCF/LEF (T-cell factor/lymphoid enhancer factor), the key downstream effector in the canonical Wnt-pathway, is frequently observed in colorectal cancer. Recent evidence indicates that the activity of b-catenin-TCF/LEF is modulated by the SUMO system. The human TCF/ LEF family consists of four homologous members, TCF-1, LEF-1, TCF-3 and TCF-4. Sachdev et al. could identify PIASy as a LEF-1 binding protein and demonstrated that PIASy stimulates SUMO modification of LEF-1. PIASy strongly repressed the activity of LEF1/b-catenin on LEF1-responsive reporter genes (Sachdev et al., 2001) . Remarkably, expression of PIASy recruits LEF-1 to PML nuclear bodies, indicating that the PIAS/SUMO system inhibits Wnt signalling by sequestering LEF-1 away from its target genes, thus neutralizing its transcriptional activity. This view has been challenged by recent findings showing that SUMOylation and NB-recruitment of the LEF-1 homologue TCF-4 by PIASy is involved in the activa-tion of the b-catenin/TCF-4 transcription factor . It remains to be elucidated how the SUMO system can integrate both negative and positive regulatory effects on Wnt signalling.
AP-1 pathway
Another important target of the SUMO system is the dimeric AP-1 transcription factor, which is composed of basic region-leucin zipper proteins of the jun, fos, maf and Atf family. Here, we focus on the functions of c-jun and c-fos. AP-1 activity is induced by stimuli that signal via mitogen-activated protein kinase cascades (Shaulian and Karin, 2002) . The downstream kinases JNK or Erk activate AP-1 by either inducing the gene expression of AP-1 proteins or by directly phosphorylating AP-1 compounds. While kinase pathways stimulate AP-1 function, SUMO modification attenuates its activity. Both c-jun and c-fos can undergo SUMO modification, and an AP-1 complex devoid of SUMOylation shows a strongly increased transactivation potential compared to wild-type AP-1 (Muller et al., 2000; Bossis et al., 2003) . Interestingly, modification of SUMO sites in either c-jun or c-fos alone has only minor effects on transcriptional activity, implying a cooperative effect of SUMO modification in transcriptional repression of AP-1. It is noteworthy that the SUMOylation of both c-jun and c-fos is stimulated by PIAS proteins (Kotaja et al., 2002b; Schmidt and Muller, 2002; Bossis et al., 2003) .
In addition to modifying c-jun and c-fos directly, SUMO appears to downregulate AP-1 activity by inhibiting the expression of c-fos. Expression of c-fos is controlled by serum response factor (SRF) and the ternary complex factor Elk-1, which form a transcription factor complex on the SRE element in the c-fos promoter. Both SRF and Elk-1 undergo SUMO modification and, consistent with a repressive role of SUMO in the AP-1 pathway, transcriptional activity of both SRF and Elk-1 is restrained by SUMOylation (Matsuzaki et al., 2003; Yang et al., 2003) . This illustrates that SUMO can inhibit upstream effectors that control the availability of an AP-1 component. The dual control of the AP-1 pathway by SUMO may have evolved to ensure a tight and coordinated regulation of AP-1 activity. Interestingly, a dynamic interplay between the activating MAPK pathways and the repressive SUMO pathway is observed in AP-1 signalling. For instance, JNK activation by cellular stress blocks SUMOylation of c-jun (Muller et al., 2000) . Conversely, a phosphomutant of c-jun with the N-terminal JNK phosphorylation sites deleted is more efficiently modified than the wild-type protein. A reciprocal regulation between the Erk kinase pathway and the SUMO system has also been observed on c-fos and Elk-1 (Bossis et al., 2003; Yang et al., 2003) .
Steroid hormone signalling
The nuclear hormone receptor pathway represents a simplified signalling pathway, since the receptors act directly as ligand-dependent transcription factors. Steroid receptors are a subgroup of the nuclear receptor superfamily and include the androgen receptor (AR), the oestrogen receptor (ER), the progesterone receptor (PR), the mineralcorticoid (MR) and the glucocorticoid receptor (GR) (Beato et al., 1995) . Upon binding of their respective ligands, the receptors form homodimers at distinct hormone response elements in the promoter region of their target genes. AR, GR and PR were shown to undergo SUMOylation within a domain that functions as a transcriptional inhibitory domain (Poukka et al., 2000; Abdel-Hafiz et al., 2002; Tian et al., 2002) . Substituting the SUMO-attachment residues within this domain enhances the transactivation potential of the receptors, again inferring an inhibitory role of SUMO in nuclear receptor signalling. Remarkably, PIAS proteins stimulate the modification of AR, GR and PR (Kotaja et al., 2002b; Nishida and Yasuda, 2002) . It is noteworthy, however, that in some contexts, the SUMO system has been shown to activate steroid receptors (Le Drean et al., 2002) . This is most likely due to the modification of the nuclear receptor coactivators of the p160 family, such as Grip1/TIF2 and SRC-1 (Jimenez-Lara et al., 2002; Kotaja et al., 2002a; Chauchereau et al., 2003) . Modification of these coactivators appears to facilitate interaction with the receptors and thereby enhances their transcriptional activity. Hence, the effects of the SUMO system on nuclear receptor-dependent gene activity likely reflect combinatorial effects on coactivators and receptors. Kotaja et al. (2002b) propose a model where SUMO modification of GRIP1 and AR occurs sequentially at different stages of the AR transcription complex formation. Initially, SUMOylation of GRIP-1 may promote its recruitment to the receptor to activate transcription. Subsequent modification of the receptor may later turn down the activity after successful initiation of the transcription process.
Mechanism of SUMO-dependent transcriptional regulation
Although SUMO can exert activating functions on transcription factors in some contexts, the common theme that emerges is that the SUMO system plays a more prominent role in gene silencing (Verger et al., 2003) . In addition to the examples described above, transcription factors that are inhibited by SUMO conjugation include the CAAT-enhancer-binding protein C/EBPa (Eaton and Sealy, 2003; Subramanian et al., 2003) , the proto-oncogene c-myb (Bies et al., 2002; Dahle et al., 2003) , the G/C element-binding protein Sp3 (Ross et al., 2002; Sapetschnig et al., 2002) , the interferon-regulated transcription factor IRF-1 (Nakagawa and Yokosawa, 2002) , the sterol regulatory element-binding proteins SREBPs (Hirano et al., 2003) and the aryl hydrocarbon receptor nuclear transporter ARNT (Tojo et al., 2002) . Activating functions and inhibitory roles of the SUMO system have also been described on Smad proteins, the downstream factors that transduce TGFb signals (Imoto et al., 2003; Lee et al., 2003; Lin et al., 2003a, b; Long et al., 2003) . In most SUMOylated transcription factors, a cKxE motif within an inhibitory or negative regulatory domain serves as a SUMO attachment site. In many cases, PIAS proteins do bind within this region and stimulate the modification by SUMO. This functional overlap of sequences that repress transcription and motifs that function as SUMO acceptor sites strongly supports a direct mechanistic correlation between SUMOylation and repression. Direct evidence for an intrinsic transcriptional repression capacity of SUMO has been obtained from experiments where SUMO is fused to the DNA-binding domain of the GAL4 transcription factor. In this context, SUMO drastically reduces the activity of the GAL4 construct in reporter gene assays (Ross et al., 2002) . Furthermore, SUMO is also able to inhibit transcription in trans as demonstrated by SUMO-dependent trans-repression of the VP-16 activation domain . Intriguingly, recent data indicate that the ubiquitin system is connected to transcriptional activation (Conaway et al., 2002; Muratani and Tansey, 2003) . In many unstable transcription factors, regions that signal ubiquitination, called degrons, overlap with transactivation domains (TAD). Consistent with this observation several E3 ubiquitin ligases bind within TADs of transcription factors and can act as transcriptional coactivators. Moreover, ubiquitination of TADs has been shown to be essential for transcriptional activation in several cases. In light of these findings, it is tempting to speculate that binding of SUMO ligases and/or SUMOylation within repression domains may act antagonistically to counterbalance TAD ubiquitination (Figure 2) . A functional interplay of the SUMO and ubiquitin system in transcriptional control would extend the concept of an antagonism between these two modifiers. A direct switch between ubiquitin and SUMO is observed on the NFkB inhibitor IkBa and proliferating cell nuclear antigen (PCNA) (Desterro et al., 1998; Hoege et al., 2002; Stelter and Ulrich, 2003) . In these two particular cases, SUMO modification occurs at the same lysine residue that is used for ubiquitination. SUMOylation of IkBa blocks ubiquitination and prevents proteasomal degradation, while in the case of PCNA, SUMOylation inhibits the ubiquitination of PCNA by the Rad6-dependent DNA damage pathway and directs PCNA to alternate functions in the S phase (see below).
Ubiquitination of transcription factors has been proposed to act as a licensing mechanism that stimulates transcriptional activity, but at the same time targets the factors for proteasomal destruction. In support of this idea, it has been demonstrated that the acetyltransferase p300, which acts as a general transcriptional coactivator for a host of transcription factors, also functions as a ubiquitin chain elongation factor . Recent data on p300 have also provided a clue on how SUMO can mediate repression of gene activity (Girdwood et al., 2003) . In addition to its functions as a coactivator, p300 can exert context-specific repressive functions. Girdwood et al. could show that this depends on SUMOylation of a distinct lysine residue within a repressor domain of p300. Most interestingly, they demonstrate a SUMO-dependent recruitment of the histone deacetylase HDAC6 to p300 and provide compelling evidence that this recruitment mediates the repressive action of p300. Members of the HDAC family are common transcriptional corepressors that catalyse the removal of acetyl groups primarily from histone tails and thereby induce gene silencing by triggering a condensed chromatin state (Verdin et al., 2003) . HDACs fall into three classes. Class I HDACs (HDAC1, 2, 3 and 8) are found in the nucleus, where they function in larger protein complexes. Class II HDACs (HDAC4-10) share a common domain with their class I cousins, but are both cytoplasmatic and nuclear, and shuttle between these two compartments. Class III HDACs are structurally unrelated NAD þ -dependent histone deacetylases. It remains to be determined whether recruitment of HDAC6 or other class II HDACs is generally involved in SUMO-mediated repression processes. Several lines of evidence indicate that the SUMO system could also play a role in the recruitment of corepressor complexes that contain class I HDACs. For instance, the inhibitory domain of AR, containing a cKxE motif, interacts with the corepressor SMRT that is part of an HDAC1-containing complex (Dotzlaw et al., 2002) . Mutation of critical residues in the SUMOconsensus motif abrogates SMRT binding, suggesting that SUMOylation is required for the association with SMRT and consequently class I HDACs. The recent finding that PIAS proteins also bind to class I HDACs provides a further link between the SUMO system and class I HDACs (Tussie-Luna et al., 2002; Long et al., 2003) .
The silencing of transcription factors by the PIAS/ SUMO system is frequently connected with the recruitment to matrix-associated subnuclear structures (Sachdev et al., 2001; Bies et al., 2002; Ross et al., 2002; Tojo et al., 2002) . In many cases, these structures overlap with PML NBs, strongly arguing for an involvement of NBs in the silencing process. Considering that transcriptional corepressors, including class I HDACs are concentrated in NBs (Khan et al., 2001) , recruitment of transcription factors to these structures could bring them in close proximity to the repressors and thereby serve to facilitate the assembly of repressor complexes. The association of PIAS with class I HDACs strengthens the idea that PIAS proteins are part of an NB-associated corepressor complex and may function in tethering this complex to SUMO-modified repressor domains within transcription factors (Tussie-Luna et al., 2002; Long et al., 2003) . Interestingly, not only the transcription factors but also HDACs and PIAS proteins are known to be SUMOylated (David et al., 2002; Kirsh et al., 2002; Kotaja et al., 2002b; Schmidt and Muller, 2002) . Hence, it is tempting to speculate that for proper formation, several components of this putative repressor complex will undergo SUMO modification. One can envisage a similar scenario to explain the activating functions of the SUMO system that are observed on some transcription factors. At least in steroid hormone signalling, the SUMO-dependent activation is linked to the assembly of a receptor coactivator complex consisting of SUMO-modified components, such as GRIP1 and SRC-1. This may also be connected to PML NBs, because GRIP1 and SRC-1 are found in NBs (Baumann et al., 2001; Rivera et al., 2003) .
In summary, in this yet speculative model SUMO, possibly together with PIAS, may be considered as a scaffolding factor or 'molecular glue' that stabilizes protein complexes or mediates their assembly. As described in detail below, this mechanism may not only be relevant for complexes involved in transcriptional processes but also for complexes acting in DNA repair and genome surveillance pathways.
SUMO modification and the control of genome integrity
Genomic DNA is continuously exposed to endogenous or exogenous agents that threaten the accuracy of genetic information by inducing different forms of DNA lesions. The repair of these lesions or the elimination of cells that have accumulated severe lesions is of crucial importance for genome integrity and tumour prevention in mammals. Therefore, highly complex DNA repair systems have evolved to cope with the different forms of DNA damage. An important feature of these systems is their tight interconnection with the DNA replication system (Hoeijmakers, 2001) . During the past few years, numerous proteins participating in DNA repair pathways have been shown to undergo SUMO modification, pointing to a role of the SUMO system in the control of these processes.
SUMO as a regulator of the PML/p53 tumour suppressor pathway
The p53 tumour suppressor pathway is a key determinant of the genotoxic stress response in mammalian cells. p53 mainly acts as an inducible, sequence-specific transcription factor on genes whose products regulate cell-cycle progression and apoptosis (Vogelstein et al., 2000) . In normal cells, the amount of p53 protein is very low since its major negative regulator, the ubiquitin ligase Mdm2 promotes p53's degradation. In response to DNA damage or cellular stress, p53 is activated by the orchestrated action of multiple posttranslational modifications, including phosphorylation of N-terminal residues by the checkpoint kinases ATM, Chk-1 and Chk-2 or the homeodomain-interacting protein kinase HIPK2, and acetylation of residues in the C-terminal region by CBP/p300 acetyltransferases (Appella and Anderson, 2001 ). These modifications either increase the stability of p53 or directly enhance its DNA-binding affinity. Additionally, p53 undergoes SUMOylation at lysine 386 within the C-terminal region (Gostissa et al., 1999; Rodriguez et al., 1999; Muller et al., 2000; Kwek et al., 2001) . The functional consequence of p53 SUMOylation has remained a matter of debate. Although an activating role on p53-mediated transcription has initially been attributed to SUMOylation, other data point to a role of the SUMO system in the repression of p53 activity. Hence, replacement of lysine 386 to arginine correlates with an activation of p53-mediated transactivation in reporter gene assays. Moreover, expression of a SUMO-isopeptidase, which cleaves SUMO from p53, stimulates p53 transactivation (Chen and Chen, 2003) , while overexpression of PIAS proteins, which induce p53 SUMOylation, is accompanied by either an up-or downregulation of p53 activity (Nelson et al., 2001; Megidish et al., 2002; Schmidt and Muller, 2002; Wible et al., 2002) . These later effects, however, are only partially linked to altered SUMO-modification of p53, because they are at least independent of lysine 386 SUMOylation. This suggests that the SUMO system targets additional factors in the p53 pathway to modulate p53 activity. Attractive candidates are the p53 regulators Mdm2, p300 and HIPK2, which all undergo SUMOylation (Kim et al., 1999; Miyauchi et al., 2002; Xirodimas et al., 2002; Girdwood et al., 2003) . However, whether and how SUMO modification of these factors influences p53 activity remains to be elucidated. An intriguing new aspect of p53 and Mdm2 SUMOylation is the apparent involvement of the nucleolus in this process, because nucleolar targeting by the p14ARF tumour suppressor stimulates the modification of both Mdm2 and p53 (Xirodimas et al., 2002; Chen and Chen, 2003) . p14ARF is known as an inhibitor of Mdm2 that protects p53 from Mdm2-mediated ubiquitination by sequestering Mdm2 in the nucleolus. Nucleolar recruitment by p14ARF is accompanied by a strong increase in Mdm2 SUMOylation. Similarly, targeting of p53 to the nucleolus enhances its SUMOylation in an Mdm2/p14ARF-dependent manner. It will be crucial to determine the particular function of SUMOylated p53/Mdm2 in the nucleolar compartment.
Another SUMO target and key regulator of p53 is the PML tumour suppressor. PML stimulates both the proapoptotic and antiproliferative capacity of p53 (Gottifredi and Prives, 2001; Pearson and Pelicci, 2001 ). Moreover, PML and p53 cooperate in the induction of cellular senescence. PML has been shown to bind p53 directly and trigger its recruitment to NBs. It has been proposed that sequestration of p53 into NBs allows the assembly of a CBP/p53 complex promoting acetylation and activation of p53. Consistent with this idea, SUMOylation of PML, a prerequisite of NB targeting, was shown to be required for PML/p53 transcriptional synergy (Fogal et al., 2000) . This concept has been questioned by the finding that the nucleoplasmic form of PML is able to trigger p53-dependent transactivation and cell-cycle arrest (Bischof et al., 2002) . Accordingly, SUMOylation of PML and intact NBs were shown to be dispensable for the induction of p53 acetylation. Recent data revealed additional mechanisms that might explain the cooperation of PML and p53. PML has been shown to stimulate Chk2-dependent phosphorylation of serine 20 in p53, which was enhanced upon induction of PML SUMOylation (Louria-Hayon et al., 2003) . Furthermore, recent data demonstrate that PML directly binds to Mdm2 and it has been speculated that this interaction may block the ligase activity of Mdm2 (Kurki et al., 2003) . Alternatively, it has been proposed that Mdm2 may trigger relocation of PML to the cytoplasm (Wei et al., 2003) . Remarkably, a PML K160R form that has lost one of the three SUMOylation sites displays a drastically increased association with Mdm2, suggesting that SUMO modification of PML is inhibitory to Mdm2 binding and hence may modulate the ligase activity of Mdm2 or control nuclear retention of PML (Wei et al., 2003) . Further studies will hopefully address this important issue.
Taken together, the currently available data on the SUMO system in the PML/p53 tumour suppressor pathway are difficult to be integrated in a unified model. We are just beginning to uncover the network of protein-protein interactions and the interplay of posttranslational modifications that may be controlled by the SUMO system.
SUMO in base excision repair
Base excision repair (BER) is the principal DNA repair system for the selective replacement of irregular bases in DNA duplexes (Hoeijmakers, 2001) . The initial step of BER is catalysed by a DNA glycosylase that recognizes and removes the aberrant base. This generates a socalled abasic site that is further repaired by a cascade of downstream enzymes, including an AP endonuclease. The rate-limiting step in BER is the release of the glycosylase from the AP site. Dissociation from AP sites is particularly slow for thymine DNA glycosylase (TDG), the enzyme that acts on G : U, and G : T mismatches to restore G : C base pairs. Hardeland et al. (2002) could show that TDG is a target for SUMOmodification and provide evidence that SUMOylation has an active role in the displacement of TDG from the AP site. In an in vitro system, SUMOylated TDG exhibits a drastically reduced DNA-binding affinity, which is associated with a significant increase in enzymatic turnover pointing to a model where unmodified TDG is the high-affinity DNA binding form that is released from the AP site by SUMO modification. Since putative SUMOylation sites are found in other human DNA glycosylases, SUMO modification may prove to have a more widespread function in BER.
SUMO in replication and homologous recombination
A frequent cause of DNA damage is the exposure of cells to irradiation or other genotoxic agents that induce DNA double strand breaks (DSB). One major pathway for DSB repair is the homologous recombination (HR) system (West, 2003) . HR is also required during normal replication since stalled or broken replication forks are re-established by the HR pathway. The two key components in the early steps of HR the RecA recombinase Rad51 and the assembly factor Rad52 are candidate SUMO-target proteins, since they interact with both Ubc9 and SUMO in the yeast-two hybrid system (Shen et al., 1996) . Although covalent modification of mammalian Rad51/52 has not yet been shown, SUMO was found in a complex with Rad51/Rad52 in mammalian cells (Li et al., 2000) . Furthermore, the orthologue of RAD52 in fission yeast S. pombe is covalently modified by SUMO in a reconstituted in vitro system (Ho et al., 2001) . A characteristic feature of Rad51/Rad52 is their accumulation in specific subnuclear foci after exposure of cells to DNA-damaging agents and in undamaged cells during the S phase. These foci are supposed to correspond to the actual sites of DNA damage or alternatively may represent assembly sites for DNA repair proteins in damaged cells. The Sphase foci presumably are sites where broken or stalled replication forks undergo repair. Importantly, impairment of the SUMO pathway by sequestering Ubc9 in the cytoplasm prevents the proper localization of RAD51 to nuclear foci in response to DNA damage, indicating that SUMO is implicated in targeting RAD51 to the site of damage (Saitoh et al., 2002) . Remarkably, Rad51 foci colocalize with a subset of PML NBs and do not form in cells that express a dominant-negative PML form, suggesting that functional PML is necessary for their assembly (Bischof et al., 2001) . Considering the crucial role of SUMO-modified PML in the assembly of NBs, it is tempting to speculate that the SUMOylation of PML or another component of Rad51 foci could also be implicated in the assembly of the foci or the recruitment of other modified proteins to these structures.
This idea is supported by the finding that other components of the Rad51 foci undergo SUMO modification. One prominent SUMO target associated with these structures is the WRN protein (Kawabe et al., 2000) . WRN localizes to the nucleolus under normal growth conditions, but relocates into Rad51 foci in response to DNA-damaging agents. WRN is a member of the RecQ family of DNA helicases and mutations in the gene encoding WRN are the cause of the hereditary disease Werner syndrome that is characterized by an increased frequency of DNA recombination and a predisposition to cancers and premature ageing (Hickson, 2003) . The cellular function of WRN and other RecQ helicases, such as Blm, are still not completely clear. It has been proposed that they act as 'roadblock' removers during replication to facilitate smooth replisome progression. An additional role in replication might be the restoration of DNA replication at sites of fork blockade. Most models for replication restart implicate the HR machinery, and there is evidence that WRN participates in the resolution of holiday junctions in HR. The particular function of the SUMO-modified form of WRN in these processes remains to be established. Notably, however, the Blm is also a candidate SUMO target, since it physically interacts with Ubc9 and SUMO (Kawabe et al., 2000) .
Intriguingly, RecQ helicases, including WRN and Blm, associate with topoisomerases, other key targets for SUMO modification in both lower and higher eukaryotes (Mao et al., 2000a, b; Bachant et al., 2002; Horie et al., 2002) . It has been suggested that the helicase/topoisomerase complex also acts in recombinatorial repair at holiday junctions (Wang, 2002) . Topoisomerases generally solve the topological problems occurring during DNA replication and other DNA transactions by catalysing DNA strand breakage and subsequent rejoining. Like WRN, topoisomerase I is predominantly localized in the nucleolus, but relocates to the nucleoplasm and distinct nuclear foci upon treatment of cells with specific topoisomerase inhibitors, such as camptothecin. These agents block the catalytic cycle of DNA breakage and religation and ultimately induce DSBs during DNA replication. Remarkably, topoisomerase inhibitors strongly stimulate SUMOylation of topoisomerase I (Horie et al., 2002; Mao et al., 2000b) and SUMOylation seems to regulate its partitioning between nucleoli and nucleoplasm, since a SUMO-deficient mutant of topoisomerase I is trapped in the nucleolus after camptothecin treatment Rallabhandi et al., 2002) . This finding substantiates the view that SUMOylation addresses proteins to specific nucleoplasmic sites in response to DNA damage. As a speculative model, we propose that SUMO regulates the subnuclear trafficking of proteins involved in recombinatorial DNA repair by targeting them to repair complexes or by sequestering them within these complexes (Figure 3) . It is noteworthy that ubiquitination has already been established as an important mechanism for targeting proteins to Rad51 foci, because mono-ubiquitination of the fanconi anaemia protein FANCD2 in response to DNA damage is required for its targeting to Rad-51 foci (Garcia-Higuera et al., 2001) .
Latest insights on SUMO function from yeast genetics
The observations summarized above provide strong circumstantial evidence that the SUMO system acts at the crossroad between DNA repair and replication. However, only recent studies in the yeast S. cerevisiae on PCNA directly demonstrated that SUMO together with ubiquitin regulates the accuracy of these processes. PCNA is essential for a variety of S-phase functions, including DNA replication, DNA repair and gene silencing. It is loaded as a trimeric ring on DNA strands and functions as a clamp and processivity factor for DNA polymerases. Hoege et al. (2002) could show that PCNA can be alternatively modified by mono-ubiquitination, K63-chain linked multi-ubiquitination and SUMOylation at a distinct lysine residue, which is conserved in the mammalian PCNA homologues. In addition, SUMO targets a second, nonconserved lysine residue in PCNA. In a series of elegant genetic experiments it was demonstrated that DNA damageinduced ubiquitination is essential in postreplicative DNA repair by the RAD6 pathway. In this process multi-ubiquitination of PCNA is elementary for the error-free branch of DNA repair, while mono-ubiquitination was proposed to trigger error-prone repair. As SUMO modification of PCNA did not support DNA repair, but was activated during the S phase, it was suggested to have a role in the S phase. Very recent work could indeed show that SUMO modification of PCNA stimulates error-prone Polz-dependent DNA synthesis during normal replication most likely to allow DNA replication at sites of fork blockade not originating from DNA damage (Stelter and Ulrich, 2003) . In summary, these data substantiate the concept that the ubiquitin/ SUMO switch on PCNA is a crucial regulatory mechanism, where SUMO modification may promote replication, while ubiquitination triggers repair processes. Although the underlying molecular mechanism is still unclear, it is reasonable to speculate that the switch of modifications may allow the exchange of binding partners on PCNA.
Conclusion and perspectives
Research on the SUMO system has now entered an exciting phase, where functional studies are following the merely descriptive era of identifying SUMO target proteins. A major challenge will be to understand the interplay of the ubiquitin and the SUMO pathways in Figure 3 Putative role of SUMO in the assembly of DNA damage foci. SUMO may regulate the subnuclear trafficking of proteins involved in recombinatorial DNA repair by targeting them to repair complexes or by sequestering them within these complexes SUMO S Müller et al transcriptional regulation, genome surveillance and presumably other cellular processes. Considering that lysine residues can undergo additional modifications, such as acetylation, we may even have to face more complex regulatory networks.
